Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

ClinicalTrials.gov ID: NCT00004584

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00004584. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 8:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination Regimen(s) as Compared to a Reference Combination Regimen(s) in Antiretroviral-Experienced HIV-Infected Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632. Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir.

Study identification

NCT ID
NCT00004584
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 1999 (Type not available)
Primary completion
Jan 2002 (Actual)
Completion
Jan 2002 (Actual)
Last update posted
May 4, 2011

1999 – 2002

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
20
Facility City State ZIP Site status
Sorra Research Ctr / Med Forum Birmingham Alabama 35203 —
AIDS Healthcare Foundation Los Angeles California 90027 —
Robert Scott MD Oakland California 94609 —
Univ of California - Davis Med Ctr / CARES Sacramento California 95817 —
Avalar Medical Group Tarzana California 91356 —
Yale Univ School of Medicine / AIDS Program New Haven Connecticut 06510 —
Community Research Initiative of South Florida Coral Gables Florida 33146 —
HIV Clinical Research Fort Lauderdale Florida 33316 —
Infectious Disease Research Institute Tampa Florida 33614 —
Infectious Disease Specialists of Atlanta Decatur Georgia 30033 —
Louisiana State Univ Med Ctr / HIV Outpatient Clinic New Orleans Louisiana 70112 —
Albany Med College Albany New York 12208 —
St Vincents Hosp / Clinical Research Program New York New York 10011 —
Univ Hosps of Cleveland Cleveland Ohio 44106 —
The Research and Education Group Portland Oregon 97210 —
Julio Arroyo West Columbia South Carolina 29169 —
Vanderbilt Univ Med Ctr Nashville Tennessee 37212 —
Univ of Texas Southwestern Med Ctr of Dallas Dallas Texas 75235 —
Texas Tech Health Sciences Ctr El Paso Texas 79905 —
Houston Clinical Research Network / Div of Montrose Clinic Houston Texas 77006 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00004584, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2011 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.